GenTraceDx for Clinicians

A Canadian National Pilot for Continuously Updating Precision Oncology
Developed with Canada’s Michael Smith Genome Sciences Centre and supported by Genome Canada and Genome BC, GenTraceDx is a living diagnostic platform designed to bring continuously updating clinical intelligence into real-world oncology care.
HOW TO JOIN

Join the GenTraceDx National Pilot

Physicians and clinical sites interested in participating in the GenTraceDx national pilot are invited to pre-enrol. Our team will follow up with enrollment and onboarding details.

Physician Registration Form

Pilot Enrolment Form - physician-login (#4)
WHY THIS MATTERS

Why GenTraceDx

Precision oncology is advancing rapidly, yet many genomic reports remain static and quickly become outdated.

GenTraceDx is designed as a continuously updating clinical intelligence system, integrating genomic data with evolving clinical evidence to support therapy selection and trial identification over time.

This approach is being evaluated through a 500-patient national pilot across Canada.
What This Means for Your Patients
  • Identify therapeutic opportunities that may not be initially apparent
  • Stay aligned with evolving clinical evidence, approvals, and guidelines
  • Access RNA-informed insights beyond traditional panel-based testing
  • Support treatment decisions with continuously updated clinical intelligence
WHAT THE PLATFORM DOES

GenTraceDx Clinical Intelligence Suite

A continuously updating clinical intelligence system designed for real-world oncology practice:
  • Living Reports: Continuously updated genomic interpretations as clinical evidence evolves
  • Real-Time Clinical Alerts: Notifications when new therapies, approvals, or evidence become relevant
  • Therapy Identification: On-label, off-label, DIN, and Special Access Program (SAP) opportunities
  • Trial Matching: Ongoing identification of relevant clinical trial options
  • Multiomic Profiling: Tumour–normal whole exome sequencing and whole-transcriptome RNA analysis
  • Tumour Board Support: Clinician-ready summaries for case review and discussion

How It Works

Step 1

Patient Enrollment

Patients are enrolled through participating institutions as part of the GenTraceDx national pilot.

Step 1

Step 2

Sample Collection & Analysis

Tumour and matched normal samples are analyzed using whole exome sequencing and whole-transcriptome RNA profiling.

Step 2

Step 3

Initial Report Delivery

Clinicians receive a comprehensive genomic report with initial therapeutic insights.

Step 3

Step 4

Continuous Reanalysis

GenTraceDx continuously integrates new clinical evidence and reinterprets patient-specific data over time.

Step 4

Step 5

Ongoing Updates

Clinicians receive real-time notifications when new therapies, approvals, or clinical trials become relevant.

Step 5

GenTraceDx National Pilot

GenTraceDx is being introduced through a 500-patient national pilot across Canada, supported by Genome Canada and Genome British Columbia and developed in collaboration with Canada’s Michael Smith Genome Sciences Centre. Participating clinicians will contribute to a national effort to evaluate and implement continuously updating precision oncology in clinical practice.
Pilot Objectives
  • Evaluate the clinical utility of continuous genomic interpretation
  • Integrate longitudinal clinical intelligence into real-world oncology workflows
  • Expand access to comprehensive multiomic analysis in clinical settings
Who Can Participate
  • Oncology centres
  • Hospitals and academic institutions
  • Licensed oncology specialists

Patient Selection

GenTraceDx may be considered for patients with:
  • Advanced, refractory, or rare malignancies
  • Unclear next-line treatment strategies
  • Limited standard-of-care options or high unmet therapeutic need
  • Potential eligibility for clinical trial participation
  • Genomically complex or ambiguous tumour profiles

Appropriate Clinical Use

  • At diagnosis, to inform treatment planning
  • At disease progression, to identify additional therapeutic options
  • Following treatment resistance, to evaluate clinical trials and off-label therapies
  • In rare or complex cancers, where panel-based testing may be insufficient

Physician Portal Access

The GenTraceDx Physician Portal is available to credentialed clinical users enrolled in the GenTraceDx national pilot (Fall 2026). Pre-enrollment is open to physicians and institutions.

To participate:
  • Submit a registration using the form above
  • Complete enrollment and onboarding before the pilot begins
  • Receive portal access prior to referring patients

Security & Compliance

  • Restricted to credentialed clinical users
  • Compliant with PHIPA and PIPEDA
  • Encrypted storage and transmission of genomic and clinical data
  • Continuous monitoring, access controls, and audit logging

Clinical Support

For platform or technical inquiries:

clinicians@gentrace.com
Secure messaging is also available within the platform for enrolled users.

Clinical Use Disclaimer

GenTraceDx is a clinical decision-support tool.
It does not replace professional judgment or institutional protocols. All treatment decisions remain the responsibility of the treating clinician.
Scroll to Top